The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform
Rachita K Sumbria - One of the best experts on this subject based on the ideXlab platform.
-
eliminating fc n linked glycosylation and its impact on dosing consideration for a transferrin Receptor Antibody erythropoietin fusion protein in mice
Molecular Pharmaceutics, 2020Co-Authors: Joshua Yang, Jiahong Sun, Demi M Castellanos, William M Pardridge, Rachita K SumbriaAbstract:Erythropoietin (EPO), a hematopoietic growth factor and a promising therapy for Alzheimer’s disease, has low permeability across the blood–brain barrier. The transferrin Receptor Antibody fused to ...
Lawrence M. Opas - One of the best experts on this subject based on the ideXlab platform.
-
Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin Receptor Antibody.
Lupus, 1997Co-Authors: J.s. Baird, Jeffrey L. Johnson, Donna D. Elliott-mills, Lawrence M. OpasAbstract:Acanthosis nigricans, insulin Receptor Antibody, and systemic lupus erythematosus are associated in the potentially lethal syndrome of type B insulin resistance. Hyperpigmentation has been reported rarely, while glucose intolerance is common in these patients. We report an adolescent girl with acanthosis nigricans, hyperpigmentation, insulin Receptor Antibody, and systemic lupus erythematosus without glucose intolerance. Insulin resistance may be mild or transient in some patients with type B insulin resistance. Resolution of skin lesions was noted during therapy of SLE, and was associated with disappearance of insulin Receptor Antibody.
Tadamitsu Kishimoto - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic uses of anti interleukin 6 Receptor Antibody
International Immunology, 2015Co-Authors: Sujin Kang, Toshio Tanaka, Tadamitsu KishimotoAbstract:Cytokine-targeted therapy has generated a paradigm shift in the treatment of several immune-mediated diseases. Interleukin-6 (IL-6), which was initially identified as B-cell stimulatory factor 2, is a prototypical cytokine with wide-ranging biological effects on immune cells such as B and T cells, on hepatocytes, hematopoietic cells, vascular endothelial cells and on many others. IL-6 is thus crucially involved in the regulation of immune responses, hematopoiesis and inflammation. When infections and tissue injuries occur, IL-6 is promptly synthesized and performs a protective role in host defense against such stresses and traumas. However, excessive production of IL-6 during this emergent process induces potentially fatal complications, including systemic inflammatory response syndrome (SIRS), and dysregulated, persistently high expression of IL-6 causes the onset or development of various chronic immune-mediated disorders. For these reasons, IL-6 blockade was expected to become a novel therapeutic strategy for various diseases characterized by IL-6 overproduction. Indeed, worldwide clinical trials of tocilizumab, a humanized anti-IL-6 Receptor monoclonal Antibody, have successfully proved its outstanding efficacy against rheumatoid arthritis, juvenile idiopathic arthritis and Castleman disease, leading to the approval of tocilizumab for the treatment of these diseases. Moreover, various reports regarding off-label use of tocilizumab strongly suggest that it will be widely applicable for acute, severe complications such as SIRS and cytokine-release syndrome and other refractory chronic immune-mediated diseases.
-
a case of behcet s disease treated with a humanized anti interleukin 6 Receptor Antibody tocilizumab
Modern Rheumatology, 2012Co-Authors: Toru Hirano, Satoshi Hohki, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Kazuyuki Yoshizaki, Nobuyuki Ohguro, Atsushi Kumanogoh, Atsushi Ogata, Tadamitsu KishimotoAbstract:A 47-year-old female patient with Behcet’s disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 Receptor Antibody, was started. This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behcet’s disease.
-
A case of Behçet’s disease treated with a humanized anti-interleukin-6 Receptor Antibody, tocilizumab
Modern Rheumatology, 2011Co-Authors: Toru Hirano, Satoshi Hohki, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Kazuyuki Yoshizaki, Nobuyuki Ohguro, Atsushi Kumanogoh, Atsushi Ogata, Tadamitsu KishimotoAbstract:A 47-year-old female patient with Behcet’s disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 Receptor Antibody, was started. This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behcet’s disease.
-
Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody
Clinical Medicine and Therapeutics, 2009Co-Authors: Yoshiyuki Ohsugi, Tadamitsu KishimotoAbstract:Evidence has accumulated indicating that proinflammatory cytokines play critical roles in the pathogenesis of RA. Recent clinical studies demonstrate that blockade of IL-6 signaling with tocilizumab, a recombinant humanized anti-interleukin-6 Receptor Antibody, is a new therapeutic option for the treatment of patients with RA refractory to conventional DMARD therapy and anti-TNF-α therapy. This paper discusses possible mechanisms of action, reviews the results of clinical trials, and discusses the place of tocilizumab in RA treatment.
-
Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 Receptor Antibody.
Annals of nuclear medicine, 2005Co-Authors: Kanji Sugimoto, Kazuyuki Yoshizaki, Tadamitsu Kishimoto, Norihiro Nishimoto, Tsunehiko NishimuraAbstract:Rheumatoid arthritis (RA) has been attributed to the abnormal production of cytokine interleukin-6 (IL-6), which has a variety of physiological activities.In vivo IL-6-Receptor imaging provides useful suggestions regarding the mechanism of anti-IL-6-Receptor Antibody action and indicates a basic therapeutic strategy for treating RA. Therefore, this study was designed to establish a method for radiolabeling anti-IL-6-Receptor antibodies and to investigate the feasibility of using radi-olabeled anti-IL-6-Receptor antibodies in the scintigraphic imaging of lesions in an animal RA model. Anti-IL-6-Receptor antibodies were conjugated with a bifunctional chelating agent, hydorazinonicotinamide (HYNIC), and radiolabeled with technetium-99m (99mTc) using the ligand exchange reaction of99mTc-tricine complex. The binding affinity was estimated using the U266 cell line. Whole body scintigraphy, biodistribution and autoradiography were undertaken in mice containing synovial cells that had been transplanted from an RA patient. Our findings showed that the antibodies accumulated in the implanted tissue. When radiolabeled anti-IL-6-Receptor antibodies are used in scintigraphic imaging, the distribution of the IL-6-Receptors is associated with the inflammatory cell infiltration that is seen in the early stage of RA. Accordingly, imaging with humanized anti-IL-6-Receptor antibodies appears to be useful for detecting early pathophysiological conditions and assessing the efficacy of Antibody treatment as well as the prognosis of patients with RA.
Carani B. Sanjeevi - One of the best experts on this subject based on the ideXlab platform.
-
TSH Receptor antibodies in subjects with type 1 diabetes mellitus.
Annals of the New York Academy of Sciences, 2006Co-Authors: Ambika Gopalakrishnan Unnikrishnan, Velayutham Kumaravel, Vasantha Nair, Ananth N Rao, Rohini V. Jayakumar, Harish Kumar, Carani B. SanjeeviAbstract:: The research was undertaken to study the prevalence of TSH Receptor Antibody positivity in patients with type 1 diabetes. A total of 74 subjects with type 1 diabetes were enrolled in this cross-sectional study. Thyroid function test and assessment of thyroid autoimmunity with anti-TPO and TSH Receptor Antibody were done in all patients. A total of 33 males and 41 females with type 1 diabetes were studied. The prevalence of TSH Receptor Antibody positivity alone was 18%. The prevalence of thyroid autoimmunity with anti-TPO as a marker was 28%; the prevalence increased to 43% when TSH Receptor Antibody was also measured. Majority of the subjects with antithyroid Antibody positivity were also positive for GAD65 antibodies. As a significant proportion of type 1 di abetic subjects have positivity to TSH Receptor Antibody, we suggest that larger studies should be conducted to study the benefits of TSH Receptor Antibody-based screening for thyroid dysfunction in type 1 diabetic subjects. As the TSH Receptor antibodies could be of the stimulating or of the blocking type, subjects with Antibody positivity could be at risk of developing hyperthyroidism or hypothyroidism.
Kunihiko Ito - One of the best experts on this subject based on the ideXlab platform.
-
TSH Receptor Antibody-associated thyroid dysfunction following subacute thyroiditis
Clinical endocrinology, 1998Co-Authors: Makoto Iitaka, Naoko Momotani, Toshihiko Hisaoka, Jaeduk Yoshimura Noh, Naofumi Ishikawa, Jun Ishii, Shigehiro Katayama, Kunihiko ItoAbstract:OBJECTIVE Autoimmunity plays an important role in the development of thyrotrophin (TSH) Receptor antibodies and the pathogenesis of Graves' disease and Hashimoto's thyroiditis. On the other hand, subacute thyroiditis is a self-limited inflammatory disease of presumed viral aetiology. The aim of this study was to examine whether subacute thyroiditis triggers TSH Receptor Antibody-associated thyroid disorders. PATIENTS We reviewed 1,697 patients with subacute thyroiditis seen between 1985 and 1995. DESIGN AND MEASUREMENTS We measured antibodies which inhibit the TSH binding to the TSH Receptor (TBIAb), thyroid stimulating antibodies (TSAb) and antibodies that block TSH action (TBAb). Other thyroid autoantibodies were also determined. RESULTS TBIAb became positive in 38 patients following subacute thyroiditis. Thyroid function after the development of TBIAb appeared to be influenced by the bioactivity of the Antibody. Hyperthyroidism developed in the presence of TSAb, and so did hypothyroidism in the presence of TBAb, although 21 patients did not have thyroid dysfunction despite high titres of TBIAb. Fifteen out of 17 patients recovered from hyperthyroidism or hypothyroidism after the disappearance of TBIAb sometimes even without medication. TBIAb-positive patients had a high incidence of a family history of thyroid disease and positive anti-thyroid microsomal antibodies. An ophthalmopathy similar to Graves' disease was also observed in 3 patients. CONCLUSIONS Subacute thyroiditis may trigger autoreactive B cells to produce TSH Receptor antibodies, resulting in TSH Receptor Antibody-associated thyroid dysfunction in some patients.
